RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

NCT07065435 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

74

Enrollment

OTHER

Sponsor class

Conditions

HER2 + Breast Cancer

Interventions

DRUG: Disitamab Vedotin (RC48)
DRUG: Bevacizumab
DRUG: Pyrotinib

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]